Cybrexa Therapeutics has reported the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board (SAB).
“We are excited to be strengthening our organization with the addition of Laurie and Nick,” said Per Hellsund, President and CEO, Cybrexa. “They bring over 50 years combined therapeutic and clinical expertise; both critical to the expansion of our leadership and advisory teams as we expand our CBX-12 clinical development program into Phase 2 clinical trials and further advance our other important pipeline assets.”